Vaccination
GSK Resources Hub
Access resources to support you and your patients.
GSK Resources Hub
Access resources to support you and your patients.
Be First To Know. Be First To Grow
Be First To Know. Be First To Grow
Quick Links
Quick Links
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com
Trademarks are owned by or licensed to the GSK group of companies
©2026 GSK group of companies or its licensor.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via P.O. Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia. Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com To report the Quality-related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com
About your privacy: GSK may monitor our technology tools and services (including email, phone, and other Communications sent to and from GSK) in order to maintain the security of systems, and to protect our staff, customers and business partners from cyber threats and loss of information. Examples of these monitoring activities include checks for offensive materials, viruses and other malignant code, and unauthorized or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may process about you, and how we use your information, click here: https://privacy.gsk.com/en-sa/privacy-notice/healthcare-professional/
PM-SA-NA-WCNT-260002 Date of Preparation: November 2026